Karen Lash
Family · Naples, FLNPI 1720392848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $963 and has fallen 69.3% since, to $295 in 2023.
Across 105 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$247
- Seagen Inc.$135
- Pfizer$128
- Amgen$126
- Novartis$124
- Incyte Corporation$123
- plus $1K from 26 others
What the payments were for
- Food & beverage$1,96498%
- Education$322%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $247 |
| Seagen Inc. | 9 | $135 |
| Pfizer | 6 | $128 |
| Amgen | 7 | $126 |
| Novartis | 7 | $124 |
| Incyte Corporation | 6 | $123 |
| Gilead | 4 | $90 |
| Jazz Pharmaceuticals Inc. | 3 | $81 |
| Bristol Myers Squibb | 3 | $79 |
| Sanofi | 4 | $70 |
| AstraZeneca | 4 | $64 |
| Merck | 3 | $61 |
| Daiichi Sankyo Inc. | 3 | $61 |
| Beigene USA, Inc. | 3 | $61 |
| Johnson & Johnson | 3 | $54 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Astellas Pharma US Inc | 3 | $47 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Dova Pharmaceuticals | 2 | $35 |
| Array Biopharma Inc | 2 | $32 |
| Puma Biotechnology, Inc. | 2 | $27 |
| Bayer | 2 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| EUSA Pharma (US) LLC | 1 | $22 |
| Sobi, Inc | 1 | $22 |
| Tersera Therapeutics LLC | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $14 |
How this compares
$1,996 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Other family in Naples
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.